Fenwick & West represented Corium International, Inc. (NAS: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, in its public offering of 6,666,667 shares of its common stock at a public offering price of $3.00 per share, excluding the underwriter’s option to purchase 1,000,000 additional shares of common stock. The offering was made pursuant to an effective shelf registration statement previously filed with the SEC.
Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering.
The Fenwick transaction team included corporate partner Robert Freedman and associates Lara Foster, Jennifer Hitchcock and Debbie Li.